Dr Reddy’s launches generic anti-viral tablets in US market

Dr. Reddy’s Laboratories has launched generic anti-viral Valganciclovir tablets in the US market. The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market yesterday and the product has been approved by the United States Food and Drug Administration ( USFDA) The tablets are generic version of Roche’s Valcyte tablets

Company Profile : Dr Reddys Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*